Dexmedetomidine suppresses the progression of esophageal cancer via miR-143-3p/epidermal growth factor receptor pathway substrate 8 axis.

abstract：:Our objectives were to study the biological activity of a novel gemcitabine-cardiolipin conjugate (NEO6002) and compare that with gemcitabine. Cytotoxicity in vitro was determined against several gemcitabine-sensitive parental and gemcitabine-resistant cancer cell lines using the sulforhodamine B assay. The in vivo to...

journal_title：Anti-cancer drugs

authors： Chen P,Chien PY,Khan AR,Sheikh S,Ali SM,Ahmad MU,Ahmad I

更新日期：2006-01-01 00:00:00

abstract：:Colchicine, the main alkaloid of the poisonous plant meadow saffron (Colchicum autumnale L.), is a classical drug used for the treatment of gout and familial Mediterranean fever. Although colchicine is not clinically used to treat cancer because of toxicity, it exerts antiproliferative effects through the inhibition o...

journal_title：Anti-cancer drugs

authors： Kumar A,Sharma PR,Mondhe DM

更新日期：2017-03-01 00:00:00

abstract：:In an effort to develop new agents and molecular targets for the treatment of cancer, aspargine-glycine-arginine (NGR)-targeted liposomal doxorubicin (TVT-DOX) is being studied. The NGR peptide on the surface of liposomal doxorubicin (DOX) targets an aminopeptidase N (CD13) isoform, specific to the tumor neovasculatur...

journal_title：Anti-cancer drugs

authors： Garde SV,Forté AJ,Ge M,Lepekhin EA,Panchal CJ,Rabbani SA,Wu JJ

更新日期：2007-11-01 00:00:00

abstract：:To investigate the apoptotic mechanism of triple-negative breast cancer (TNBC) cells induced by gefitinib and PI3K inhibitor SF1126. MDA-MB-231, MDA-MB-436, and MCF-7 cells were incubated with 0.1 μmol/l gefitinib, 1 μmol/l gefitinib, 10 μmol/l gefitinib, 1 μmol/l SF1126, 0.1 μmol/l gefitinib+1 μmol/l SF1126, 1 μmol/l...

journal_title：Anti-cancer drugs

authors： Deng M,Wang J,Chen Y,Zhang L,Liu D

更新日期：2015-04-01 00:00:00

abstract：:Topical treatment of skin metastases with a cytotoxic agent is attractive for its easy self-administration and absence of major systemic interference. Miltefosine exerts its cytotoxicity by acting on cell membrane phospholipids and can be administered topically. Twenty breast cancer patients with progression of skin m...

journal_title：Anti-cancer drugs

authors： Smorenburg CH,Seynaeve C,Bontenbal M,Planting AS,Sindermann H,Verweij J

更新日期：2000-11-01 00:00:00

abstract：:A review of the chemotherapeutic agents which have been developed by targeting DNA topoisomerase I and II is presented. Camptothecins as topoisomerase I-targeting agents and newly developed topoisomerase II-targeting agents with unique properties are expected to be promising anticancer agents in the near future. An im...

journal_title：Anti-cancer drugs

authors： Takano H,Kohno K,Matsuo K,Matsuda T,Kuwano M

更新日期：1992-08-01 00:00:00

abstract：:Since the early 1990s, mitoxantrone has been used as a chemotherapeutic agent for adjuvant intravesical treatment following transurethral resection of superficial transitional cell carcinomas of the bladder. Although its efficacy as adjuvant intravesical therapy remains questionable and its use has not gained wide acc...

journal_title：Anti-cancer drugs

authors： Giannakopoulos S,Pantazis T,Kalaitzis C,Antoniou D,Patris E,Touloupidis S

更新日期：2008-03-01 00:00:00

abstract：:The tetracycline family includes tetracycline, doxycycline and minocycline, all of which have been used as antibiotics effectively for decades. New uses emerged for these compounds after their effect on mitochondrial function was discovered. Cytostatic and cytotoxic activity of these compounds was shown against cell l...

journal_title：Anti-cancer drugs

authors： Saikali Z,Singh G

更新日期：2003-11-01 00:00:00

abstract：:We measured serum levels of soluble (s) P-selectin and thromboxane B2 (TxB2) in patients with lung cancer treated with gefitinib, and investigated the effect of low-dose aspirin on some adverse effects of gefitinib. The serum levels of sP-selectin and TxB2 increased significantly in all patients who received gefitinib...

journal_title：Anti-cancer drugs

authors： Kanazawa S,Yamaguchi K,Kinoshita Y,Muramatsu M,Komiyama Y,Nomura S

更新日期：2006-04-01 00:00:00

abstract：:Imatinib is the standard first-line therapy for metastatic gastrointestinal stromal tumors. It has markedly improved the prognosis and outcome of patients affected by gastrointestinal stromal tumors, especially in the case of exon 11 KIT mutations. Imatinib-associated adverse events are generally mild to moderate; how...

journal_title：Anti-cancer drugs

authors： Saponara M,Gatto L,Di Nunno V,Tabacchi E,Fanti S,Di Scioscio V,Nannini M,Gruppioni E,Altimari A,Fiorentino M,Santini D,Ceccarelli C,Zompatori M,Biasco G,Pantaleo MA

更新日期：2016-04-01 00:00:00

abstract：:5-Fluorouracil (5-FU) is the most widely used agent for the management of colorectal cancer. Capecitabine is metabolized by three enzymatic actions, the last of which is mediated by thymidine phosphorylase, to produce 5-FU. Given the oral bioavailability of capecitabine as well as in-vitro and in-vivo findings showing...

journal_title：Anti-cancer drugs

authors： Patel PA

更新日期：2011-04-01 00:00:00

abstract：:Renal cell carcinoma (RCC) is one of the most frequent malignancies of the adults. Its incidence has been increasing steadily by 2-4% each year. Up to 30% of patients present with metastases at diagnosis. It is a highly vascularized cancer because of the hypoxia-induced factor stabilization as a consequence of von Hip...

journal_title：Anti-cancer drugs

authors： Nigro O,Pastore A,Tartaro T,Bolzacchini E,Tuzi A,Pinotti G

更新日期：2019-04-01 00:00:00

abstract：:The beta-carboline alkaloids are naturally existing plant substances. It is known that these alkaloids have a wide spectrum of neuropharmacological, psychopharmacological, and antitumor effects. Therefore, they have been traditionally used in oriental medicine for the treatment of various diseases including cancers an...

journal_title：Anti-cancer drugs

authors： Abe A,Yamada H

更新日期：2009-06-01 00:00:00

abstract：:Our study aimed to further investigate the roles and molecular mechanisms of lncRNA taurine upregulated gene 1 (TUG1) in the development and progression of PC. RT-qPCR assay was carried out to measure expression of TUG1, miR-496, together with β-catenin, cyclin D1 and c-myc. Protein levels of β-catenin, cyclin D1 and ...

journal_title：Anti-cancer drugs

authors： Li G,Yang J,Chong T,Huang Y,Liu Y,Li H

更新日期：2020-07-01 00:00:00

abstract：:α-Lipoic acid (α-LA) is a biogenic antioxidant that has been used successfully in the treatment of diabetic polyneuropathy and its application to many oxidative stress-associated chronic diseases has increased. In this study, we investigated the effect of α-LA on colorectal cancer cell growth and its underlying mechan...

journal_title：Anti-cancer drugs

authors： Yoo TH,Lee JH,Chun HS,Chi SG

更新日期：2013-07-01 00:00:00

abstract：:We have previously shown that L-methionine inhibits proliferation of breast, prostate, and colon cancer cells. This study extends these findings to BXPC-3 (mutated p53) and HPAC (wild-type p53) pancreatic cancer cells and explores the reversibility of these effects. Cells were exposed to L-methionine (5 mg/ml) for 7 d...

journal_title：Anti-cancer drugs

authors： Benavides MA,Bosland MC,da Silva CP,Gomes Sares CT,de Oliveira AM,Kemp R,dos Reis RB,Martins VR,Sampaio SV,Bland KI,Grizzle WE,dos Santos JS

更新日期：2014-02-01 00:00:00

abstract：:It is well known that the anti-cancer drug cisplatin has an ototoxic property; however, the details are not yet evident. In this study, the expression of inducible nitric oxide synthase (INOS/NOS II) in the vestibule of guinea pigs after i.p. injections of cisplatin was examined immunohistochemically. Three days after...

journal_title：Anti-cancer drugs

authors： Watanabe K,Hess A,Bloch W,Michel O

更新日期：2000-01-01 00:00:00

abstract：:Lung cancer is considered the number one killer among all cancers. Recent observations have altered the treatment paradigm for non-small-cell lung cancer (NSCLC). The discovery of activating mutations in the epidermal growth factor receptor and anaplastic lymphoma kinase positivity has made personalized treatment for ...

journal_title：Anti-cancer drugs

authors： Petrosyan F,Daw H,Haddad A,Spiro T

更新日期：2012-11-01 00:00:00

abstract：:Octreotide appears to have a major therapeutic effect in the management of diarrhoea related to cancer therapy. This effect is seen in the acute diarrhoea following radiation therapy and chemotherapy, and also in late radiation enteritis. As well as providing improved symptom control, early treatment can prevent poten...

journal_title：Anti-cancer drugs

authors： Baillie-Johnson HR

更新日期：1996-01-01 00:00:00

abstract：:Amifostine is a broad-spectrum cytoprotective agent approved for protection against cisplatin toxicities and radiation-induced xerostomia; strong clinical evidence exists that amifostine protects normal mucosa and lung from radiation damage. Hypotension, nausea/vomiting, fatigue and fever/rash are the main side-effect...

journal_title：Anti-cancer drugs

authors： Koukourakis MI,Maltezos E

更新日期：2006-02-01 00:00:00

abstract：:A new dosage formulation of 5-fluorouracil incorporated in microspheres (5-FU-MS) was developed for the treatment of peritoneal carcinomatosis. We studied the acute toxicity and side effects of i.p. 5-FU-MS in mice. The 50% lethal dose value for 5-FU-MS was 535.4 mg/kg of 5-FU, which was 2.22 times that of the aqueous...

journal_title：Anti-cancer drugs

authors： Hagiwara A,Sakakura C,Tsujimoto H,Ohgaki M,Imanishi T,Yamazaki J,Sawai K,Takahashi T,Yamamoto A,Muranishi S,Tabata Y,Ikada Y

更新日期：1996-09-01 00:00:00

abstract：:Docetaxel has shown promise for the treatment of hormone-refractory prostate cancer and has become the standard of care. The flare phenomenon is a known entity in androgen-deprivation therapy of advanced prostate cancer and it has also been described in palliative chemotherapy of hormone-refractory prostate cancer. Th...

journal_title：Anti-cancer drugs

authors： Olbert PJ,Hegele A,Kraeuter P,Heidenreich A,Hofmann R,Schrader AJ

更新日期：2006-09-01 00:00:00

abstract：:The therapeutic effects of the new anti-angiogenesis factor TNP-470 were examined against carcinomatous peritonitis in mice. In the first experiment using carcinomatous peritonitis caused by i.p. inoculation of 10(6) M5076 tumor cells, TNP-470 solution was injected i.p. in a bolus of 50 mg/kg body weight into two grou...

journal_title：Anti-cancer drugs

authors： Tsujimoto H,Hagiwara A,Osaki K,Ohyama T,Sakakibara T,Sakuyama A,Ohgaki M,Imanishi T,Watanabe N,Yamazaki J

更新日期：1995-06-01 00:00:00

abstract：:The objective of this study was to detect the effect of NADPH oxidase (NOX) inhibition on metastasis of lung cancer. Primary human lung cancer cells were isolated from surgical tissues using the Cancer Cell Isolation Kit. Invasion was detected using the BD Biocoat Matrigel Invasion Chamber assay. Expressions of microR...

journal_title：Anti-cancer drugs

authors： Yan S,Liu G,Pei C,Chen W,Li P,Wang Q,Jin X,Zhu J,Wang M,Liu X

更新日期：2015-04-01 00:00:00

abstract：:Para-toluenesulfonamide (PTS), active ingredient being PTS, is a new anticancer drug applied through local intratumoral injection. The aim of this phase II clinical trial was to investigate the response and toxicity of standard gemcitabine (GEM) plus cisplatin (CIS) chemotherapy with concurrent intratumoral injection ...

journal_title：Anti-cancer drugs

authors： He J,Ying W,Yang H,Xu X,Shao W,Guan Y,Jiang M,Wu Y,Zhong B,Wang D,Tucker S,Zhong N

更新日期：2009-10-01 00:00:00

abstract：:Systemic chemotherapy for patients with a good performance status and advanced non-small cell lung cancer may result in prolonged survival and improved quality of life. However, few single agents have an activity of more than 15% and they have significant toxicity. Cisplatin is widely regarded as the single agent of c...

journal_title：Anti-cancer drugs

authors： Abratt RP

更新日期：1995-12-01 00:00:00

abstract：:The dose-limiting toxicities of the DNA topoisomerase I inhibitor topotecan are hematological. We prospectively analyzed the platelet toxicity pattern in patients receiving topotecan to optimize the clinical management of topotecan hematotoxicity. Twenty-one advanced ovarian cancer patients, all pretreated with cispla...

journal_title：Anti-cancer drugs

authors： Goldwasser F,Buthaud X,Gross M,Bleuzen P,Cvitkovic E,Voinea A,Jasmin C,Romain D,Misset JL

更新日期：1999-03-01 00:00:00

abstract：:Paclitaxel and docetaxel are excellent agents with a high antitumor effect for the treatment of previously anthracycline-exposed metastatic breast cancer. There has been no standard treatment for patients who undergo therapy of a taxan-resistant metastatic breast cancer. Paclitaxel has partial non-cross-resistance in ...

journal_title：Anti-cancer drugs

authors： Suzuma T,Sakurai T,Yoshimura G,Umemura T,Tamaki T,Naito Y

更新日期：2000-08-01 00:00:00

abstract：:Since 5-fluorouracil (5-FU) was synthesized in the late 1950s it has become an important component of many anticancer treatment regimens. The increasing volume of literature accumulating about this drug is evidence that the optimal administration schedule and its combination with modulators has yet to be determined. M...

journal_title：Anti-cancer drugs

authors： Findlay MP,Leach MO

更新日期：1994-06-01 00:00:00

abstract：:The anticancer drug candidates 1,3-dibenzyl-4,5-diphenyl-imidazol-2-ylidene gold(I) dimethylamino dithiocarbamate and 2,3,4,6-tetra-O-acetyl-α-D-glucopyranosyl-1-thiolate derivative exhibited nanomolar in-vitro activity against prostate cancer cells advanced prostate cancer (PC3) and micromolar inhibition of mammalian...

journal_title：Anti-cancer drugs

authors： Walther W,Althagafi D,Curran D,O'Beirne C,Mc Carthy C,Ott I,Basu U,Büttner B,Sterner-Kock A,Müller-Bunz H,Sánchez-Sanz G,Zhu X,Tacke M

更新日期：2020-08-01 00:00:00